Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04755244 · ClinicalTrials.gov registry record · Phase 1
A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05)
A Phase 1 study, sponsored by ALX Oncology.
- Terminated
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT04755244: Clinical Trial Phase 1 study, sponsored by ALX Oncology.
NCT04755244 is a Phase 1 study that was terminated before completion, run by ALX Oncology. The registered enrollment target is 14 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04755244, a Phase 1 study, was terminated before completion, sponsored by ALX Oncology.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
This Phase 1/2 clinical study will evaluate evorpacept (ALX148) in combination with venetoclax and azacitidine for the treatment of patients with acute myeloid leukemia (AML).
Primary Outcome
Number of participants with a DLT
Interventions
- DRUG venetoclax
- DRUG azacitidine
- DRUG evorpacept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2021-05-05 |
| Est. Completion | 2023-08-16 |
| Phase | Phase 1 |
Why NCT04755244 stopped before completion
NCT04755244 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 3 interventions - of which venetoclax is the first listed.
NCT04755244 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04755244 about?
NCT04755244 is a clinical study titled "A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05)". This Phase 1/2 clinical study will evaluate evorpacept (ALX148) in combination with venetoclax and azacitidine for the treatment of patients with acute myeloid leukemia (AML).
What is the current status of trial NCT04755244?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2021-05-05. Estimated completion is 2023-08-16.
What interventions are being tested in trial NCT04755244?
The interventions under investigation include: venetoclax (DRUG), azacitidine (DRUG), evorpacept (DRUG).
Who is sponsoring clinical trial NCT04755244?
This trial is sponsored by ALX Oncology, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04755244's enrollment target sits among peer trials
14 1844th of 2000 higher than 154 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy